Aduro BioTech, Inc. (Aduro)

Oncology Corporate Profile

HQ Location

626 Bancroft Way, #3C
Berkeley, CA 94710

Company Description

Aduro BioTech, Inc. is a clinical-stage immunotherapy company located in Berkeley, California. Aduro has completed a randomized, controlled Phase 2 clinical trial in patients with metastatic pancreatic cancer and is conducting a Phase 1B trial in patients with malignant pleural mesothelioma. The company's pipeline also includes preclinical programs in glioblastoma, prostate cancer, melanoma, malaria, HBV and tularemia.

Website: http://www.adurobiotech.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
CRS-207 (+ antiPD-1)immunotherapyGastric cancerII
CRS-207 (+ antiPD-1)immunotherapyMesotheliomaII
GVAX vaccine / CRS-207immunotherapyMesotheliomaII
GVAX vaccine / CRS-207immunotherapyPancreaticII
ADU-623immunotherapyGlioblastoma Multiforme (GBM)I
ADU-741immunotherapyNon Small Cell Lung Cancer (NSCLC)IJanssen
GVAX vaccine / CRS-207immunotherapyOvarian cancerI
CRS-207 (+ antiPD-1)immunotherapyOvarian cancerIIncyte
ADU-741immunotherapyProstate cancerIJanssen
ADU-214immunotherapyNon Small Cell Lung Cancer (NSCLC)Preclinical
ADU-214immunotherapyOvarian cancerPreclinical

View additional information on product candidates here »

Pipeline image

Source


http://www.adurobiotech.com/

Recent News Headlines

There are no news items to display